Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Alnylam Pharmaceuticals IncALNY-107.6917.081,106.11-271.67199.53%-4.84%62.32$272.51$602.1928,064$278.27

Detail of Alnylam Pharmaceuticals Inc

 
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Employees
1665
Industry
Biotechnology
Sector
Healthcare
Market cap
$36B

Company details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$2.09B
Cost of goods (CoG)
-$306.41M
Gross profit (GP)
$1.79B
Operating expense (OE)
-$1.98B
Research and development (R&D)
-$1.10B
General and administrative (G&A)
-$878.31M
Operating income (OI)
-$188.13M
Other income expense (OIE)
-$120.13M
Pretax income (PI)
-$321.10M
Tax (TAX)
-$11.16M
Net income (NI)
-$332.26M
Alnylam Pharmaceuticals Inc
ALNY • XNGS • US
$278.27
+109.65 (65.04%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.58
Margin profit
-15.86%
52 week low
$143.309998
52 week high
$300.549988
50-day simple moving average
$273.81
200-day simple moving average
$272.51
Percent held by insiders
0.43%
Percent held by institutions
98.15%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ALNY +64.16%
eps change
ALNY -173.73%